OncoMatch/Clinical Trials/NCT07188558
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Is NCT07188558 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including rondecabtagene autoleucel and axicabtagene ciloleucel for large b-cell lymphoma.
Treatment: rondecabtagene autoleucel · axicabtagene ciloleucel · lisocabtagene maraleucel — This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Allowed: MYC rearrangement
DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
Allowed: BCL2 rearrangement
DLBCL/High-grade B-cell lymphoma (HGBCL) with MYC and BCL2 rearrangements
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-CD20 antibody — first-line
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
Must have received: anthracycline-containing chemoimmunotherapy — first-line
Relapsed or refractory disease after anti-CD20 antibody and anthracycline-containing first-line chemoimmunotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Honor Health · Scottsdale, Arizona
- Mayo Clinic Arizona · Scottsdale, Arizona
- University of Arkansas · Little Rock, Arkansas
- Cedars-Sinai Medical Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify